Elizabeth Holmes had more resources, talent, and opportunity than most founders will ever see — and she blew it. Now, writes ...

In a world first, scientists used CRISPR to fix a baby's unique genetic mutation. The report offers hope for personalized ...

A top agency official is meeting with industry and FDA staff as he works on guidance clarifying the FDA’s expectations for ...

Republicans on the House Appropriations Committee lauded the Make America Healthy Again movement on Wednesday while pushing ...

Meanwhile, at STAT’s Breakthrough Summit West in San Francisco, former FDA Commissioner Robert Califf criticized RFK Jr.’s ...

Lurking beneath the shiny promise of artificial intelligence in health care is a host of potential liability issues, experts ...

CMS and ASTP, the health department’s health IT regulator, released a request for information this week about existing ...

Lowering drug prices to European benchmarks would ultimately reduce innovation and cost American consumers just over half a ...

Research leaders voiced concerns about attacks on diversity efforts, grant terminations, and fear among scientists at #STATBreakthrough.

How likely is it for President Trump's new drug-pricing plan to be implemented? And will we see a return of Elizabeth Holmes' blood-testing ambitions? All that and more on "The Readout LOUD" podcast.

Good morning! Despite believing that headlines on STAT stories are “terrible,” former FDA head Robert Califf said at ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...